Effects of suppressing bioavailability of insulin-like growth factor on age-associated intervertebral disc degeneration

Rebecca Kritschil1 | Zhongying Zhang1,2 | Changbin Lei1,3 | Jiongbiao Zhong1,4 | Qing Dong1 | Joon Lee1 | Cheryl A. Conover5 | Gwendolyn Sowa1,6 | Abbe N. Vallejo7 | Nam Vo1

1Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
2Department of Orthopedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
3Department of Orthopaedic Surgery, First Affiliated Hospital of Jinan University, Guangdong, China
4Department of Spinal Surgery, The First Affiliated Hospital of University of South China, Hengyang, Hunan, P.R.China
5Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota
6Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania
7Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania

Correspondence
Nam Vo, Department of Orthopedic Surgery, University of Pittsburgh, 200 Lothrop Street, E1644 Biomedical Science Tower, Pittsburgh, PA 15261.
Email: von@upmc.edu

Funding information
Commonwealth of Pennsylvania: CURE Program Award; American Federation for Aging Research, Grant/Award Number: M12589; US Public Health Service, National Institutes of Health, National Institute on Aging, Grant/Award Number: R01 AG044376

Abstract
Suppression of the insulin-like growth factor-1 (IGF-1) signaling pathway reduces age-related disorders and increases lifespan across species, making the IGF-1 pathway a key regulator of aging. Previous in vitro intervertebral disc cell studies have reported the pro-anabolic effect of exogenously adding IGF-1 on matrix production. However, the overall effects of suppressing IGF-1 signaling on age-related intervertebral disc degeneration (IDD) is not known. Here, the effects of suppressing IGF-1 signaling on age-related IDD in vivo were examined using PAPPA−/− mice. These are animals with targeted deletion of pregnancy-associated plasma protein A (PAPPA), the major protease that cleaves inhibitory IGF binding proteins that control bioavailability of IGF-1 for cell signaling. Compared to age-matched wild-type (Wt) littermates, reduced levels of matrix proteoglycan (PG) and aggrecan were seen in discs of 23-month old PAPPA−/− mice. Decreased aggrecan synthesis and expression of two key catabolic markers, matrix metalloproteinase-3 and a disintegrin and metalloproteinase with thrombospondin motifs-4, were also observed in discs of old PAPPA−/− mice compared to Wt littermates. Suppressing IGF-1 signaling has been implicated to shift cellular metabolism toward maintenance rather than growth and decreasing cellular senescence. Along this line, discs of old PAPPA−/− mice also exhibited lower cellular senescence, assessed by p53 and lamin B1 markers. Collectively, the data reveal complex regulation of disc matrix homeostasis by PAPPA/IGF-1 signaling during chronologic aging, that is, reduced IGF-1 bioavailability confers the benefit of decreasing disc cellular senescence and matrix catabolism but also the disadvantage of decreasing disc PG matrix anabolism. This pathway requires further mechanistic elucidation before IGF-1 could be considered as a therapeutic growth factor for treating IDD.

KEYWORDS
aging, cellular senescence, IGF-1, intervertebral disc degeneration, PAPPA, proteoglycan
INTRODUCTION

Growth factors are peptides working in an autocrine or paracrine manner to regulate cellular activity by binding to cell surface receptors and initiating downstream signaling in target cells. Insulin-like growth factors (IGF) are involved in proliferation and function of nearly every cell, tissue, and organ in the body. IGF-1 is one of two signaling proteins in the IGF family that binds to IGF-1 receptor (IGF-1R). IGF-1 signaling is a well-established modulator of aging. Genetic and pharmacologic suppression of the IGF-1 signaling pathway in numerous animal models has consistently shown that decreasing IGF-1 signaling leads to healthier aging and increased lifespan. Mutations known to impair IGF-1 receptor function, such as natural polymorphisms of the IGF1R gene, and other genetic alterations that affect IGF-1 signaling, have been found in numerous populations of centenarians around the world from Japan to New England. The exact mechanisms of how the IGF-1 pathway increases longevity in mammals is unknown, highlighting the complexity of this signaling pathway. However, it has been suggested that decreasing IGF-1 signaling reduces mTOR and shifts cellular metabolism from cell growth to cell maintenance and repair activities, decreasing the accumulation of senescent cells. Despite some inconsistent findings on the role of IGF-1 Among human centenarian and animal model studies, there is overwhelming evidence to support that disruptions to the IGF-1 signaling pathway promotes healthy longevity.

Intervertebral disc degeneration (IDD) can be initiated by an imbalance in disc matrix homeostasis, leading to a pathologic catabolic state where more extracellular matrix is being degraded than what can be produced by disc cells. IDD can lead to biomechanical instability and a range of spine problems, including low back pain. Growth factors such as IGF-1 are an attractive biologic therapeutic for treating IDD because they are able to stimulate anabolic production of extracellular matrix. Early studies on disc cell culture and IGF-1 stimulation showed increased proteoglycan (PG) synthesis of nucleus pulposus (NP) cells in bovine and canine models. More recently, IGF-1 has been shown to stimulate both DNA synthesis and downstream signaling of bovine NP and annulus fibrosus (AF) cells in vitro. Additionally, another in vitro study showed the beneficial effect of IGF-1 on decreasing senescent cells in human AF cells exposed to hydrogen peroxide, suggesting a protective effect of IGF-1 against oxidative stress that is typically observed in aging disc. The growing research interest in the role of IGF-1 in IDD has given rise to the idea that IGF-1 can be used as a therapeutic to treat IDD.

The therapeutic potential of IGF-1 for treating IDD, however, is complex and unclear. There is evidence supporting the use of IGF-1 to treat IDD patients in vivo based on reported decreased levels of serum IGF-1 in IDD patients. These studies have correlated low circulating IGF-1 levels with increased level of IDD. However, circulating IGF-1 level is also influenced by age, sex, and BMI, all of which influence the risk of developing IDD. Therefore, adjustments for these factors in control vs patient groups are imperative for correctly evaluating IGF-1 levels in control subjects vs patients with IDD. Likewise, circulating IGF-1 levels do not reflect individual tissue concentrations. Free unbound IGF-1 or IGF-1 bioavailability, in the disc specifically, is a better measure of the activity of the GH/IGF-1 pathway in relation to IDD rather than total serum or total protein expression level, which are the methods used almost exclusively in previous papers studying IGF-1 and IDD.

Aging is a well-established major risk factor of IDD as discs appear to undergo age-related degenerative changes earlier in life than other tissues. However, the role of IGF-1 signaling in regulating age-related IDD is unknown. On the one hand, in vitro disc studies suggest that increasing IGF-1 signaling promotes disc health through stimulating matrix production. On the other hand, decreasing IGF-1 signaling in vivo has been shown to mediate age-related disorders and increase lifespan. In light of these conflicting findings, this study investigated how IGF-1 signaling regulates disc aging in vivo using PAPPA−/− mice. These are animals with targeted deletion of pregnancy-associated plasma protein A (PAPPA), a gene encoding a protease that specifically cleaves three of the IGF binding proteins—IGFBP-2, -4, and -5—that sequester IGF-1 and reduce its bioavailability. The PAPPA amino acid sequence contains five short consensus repeats in its C terminus. Two of these repeats, SCR3 and SCR4, are glycosylated and mediate the binding of PAPPA to cell surface. Because of its location at the cell surface, PAPPA is responsible for the local IGF-1 bioavailability and IGF-1 signaling activity more than the circulating level of IGF-1. The mean lifespan for PAPPA−/− mice is approximately 40% greater than wild-type (Wt) mice. In this study, the effects of reduced IGF-1 bioavailability on disc matrix homeostasis and age-related IDD in 23-month old PAPPA−/− mice and their Wt littermates were investigated.

METHODS

2.1 Mice

Creation, genotype, and genetic screening of PAPPA−/− mice and their Wt littermates have been reported elsewhere. Gene profiles and pathological assessments over the lifespan have also been reported. Animals were reared in specific-pathogen free facility. For this study, 23-month-old mice were used, their spines collected and analyzed. Six-month-old Wt mice were also included in analysis of disc aggrecanolysis. The number of animals used in each experiment are as indicated in the figure legends. All studies were performed according to animal research protocols approved by Institutional Animal Care and Use Committees of the University of Pittsburgh.

2.2 Aggrecanolysis

To measure disc aggrecan fragmentation, seven caudal discs were pooled to prepare extract for immunoblots using a previously established method. Anti-aggrecan primary antibody (1:1000 dilution, Abcam ab36861, Cambridge, United Kingdom) and anti-rabbit horse radish peroxidase secondary antibody (1:5000 dilution, Thermo Scientific) were used.
Scientific PI-31460, Waltham, MA, USA), were used for Western blot detection of aggrecan proteolytic fragments.

### 2.3 Western blotting

Protein from caudal discs of seven mice were extracted using Tissue Protein Extraction Reagent (T-PER) with proteinase inhibitor cocktail per the manufacturer's instructions (Thermo Fisher 78510, Waltham, MA). Western blotting for the expression of p53, matrix metalloproteinase-3 (MMP-3), and a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) was also performed. Primary antibodies (1:1000 dilution) to p53 (Cell Signaling Technology 2524, Danvers, MA), MMP-3 (Abcam ab52915, Cambridge, United Kingdom), ADAMTS-4 (Abcam ab185722, Cambridge, United Kingdom), and β-actin (Thermo Fisher PA1-183, Waltham, MA) and secondary anti-rabbit horse radish peroxidase antibody (1:5000 dilution, Thermo Fisher 31460, Waltham, MA) were used.

Following electrophoresis on Tris-HEPES 4%-20% gradient polyacrylamide denaturing gel (Thermo Scientific 25204, Waltham, MA), separated proteins were transferred to a polyvinylidene difluoride membrane. Signals were measured using chemiluminescent detection (Thermo Scientific 34096, Waltham, MA) and ChemiDoc MP system (Bio-Rad, Hercules, CA). The protein bands were analyzed using NIH Image J 1.44p with local background subtraction. The data obtained were normalized with β-actin.

### 2.4 Histology

Isolated lumbar disc tissues from three PAPPA−/− and Wt mice were fixed and decalcified in Decacifier I solution (Leica 3800440) at 4°C overnight. All tissues were dehydrated through a graded alcohol series and then embedded in paraffin (Tissue Tek processor and Leica Embedder) and cut into three 4-μm thick sections in the coronal plane. The sections were stained with safranin-O and fast green dyes by standard procedures and photographed under ×40 to ×200 magnification (Nikon Eclipse E 800).

### 2.5 Immunohistochemistry

Detection of aggrecan and lamin B1 were performed on deparaffinized coronal disc tissue sections of 4-μm thickness. The sections were pretreated with chondroitinase ABC degrades chondroitin sulfate A, chondroitin sulfate B, and chondroitin sulfate C (0.25 U/mL; Sigma C3667, St. Louis, MO) at 37°C for 1-hour to unmask epitopes. Endogenous peroxidase activity was eliminated by the treatment with 3% hydrogen peroxide, and then incubated 15 minutes with Avidin D solution and 15 minutes with biotin solution (Vector Laboratories SP-2001, Burlingame, CA). Permeabilization and blocking was done with 10% goat serum, 1% bovine serum albumin, and 0.25% Triton-X 100 in phosphate buffered saline for 30 minutes. Primary antibody against Aggrecan (1:200; EMD Millipore AB1031) and lamin B1(1:1000; Abcam ab16048, Cambridge, United Kingdom) were applied at 4°C overnight, then thoroughly washed with washing buffer (PBS + 0.05% Tween20). Biotinylated goat anti-rabbit secondary antibody (1:200; Vector Laboratories BA-1000, Burlingame, CA) was applied for 30 minutes and the sections were washed again in washing buffer, followed by the avidin-biotin amplification (Vector Laboratories PK-6100, Burlingame, CA) for 30 minutes. AEC substrate/chromogen KIT (ScyTek Laboratories ACG500) was used for 10 minutes. Hematoxylin was used as a counterstain. All mounted slides with mounting medium Cytoseal 60 (Thermo Fisher Scientific 8310-4, Waltham, MA) were visualized on a Nikon Eclipse E800 microscope.

### 2.6 DMMB assay for total glycosaminoglycan

PG content of disc NP from Wt and PAPPA−/− mice was measured using 1,9-dimethylmethylene blue buffer (DMMB) assay for total glycosaminoglycan (GAG). NP tissue from three lumbar discs of each mouse was isolated using the dissecting microscope and stored at −80°C. The tissue was digested in papain (Sigma–Aldrich P4762, St. Louis, MO) under standard methods.22 Samples were prepared in DMMB (Sigma–Aldrich 341088, St. Louis, MO), and the optical density was read at 540 nm and compared with established standards for chondroitin sulfate (Sigma–Aldrich C-8529, St. Louis, MO). The GAG content was normalized based upon DNA concentration of each sample; this was measured using the Pico green dsDNA quantitation kit (Thermo Fisher Scientific P7589, Waltham, MA).

### 2.7 Statistical analysis

Data are expressed as the mean ± SD of three independent samples. For Western blot and total GAG analysis, 95% confidence intervals were calculated to determine statistical significance at P < .05 level. The confidence intervals were calculated based on the t-distribution because of the small sample size.33

### 3 RESULTS

#### 3.1 Aged PAPPA−/− mice exhibit decreased disc PG matrix content

Progressive loss of disc PG matrix occurs with age. To determine whether decreasing IGF-1 signaling in the disc influences the amount of disc PG in old mice, safranin-O/fast green histological staining was performed. The intensity of safranin-O staining was reduced in the lumbar discs of 23-month-old PAPPA−/− mice compared to their Wt littermates (Figure 1A). Disc histological scoring also reveal slightly higher AF fissure formation and greater loss of NP matrix and NP-AF boundary in PAPPA−/− mice compared to their Wt control (Figure 1A), although these differences are not statistically different (Table 1).
GAGs are covalently attached to PGs and are responsible for providing the osmotic properties necessary for normal disc tissue compression. This functional ability is dependent on a high concentration of GAGs and a decrease in GAGs is a hallmark of both disc aging and IDD. Consistent with the safranin-O histological staining, DMMB assay for quantitative measurement of GAG content, a surrogate marker for PG, revealed 2.6-fold less disc GAG in aged PAPPA\(^{-/-}\) mice compared to aged Wt littermates (Figure 1C). Immunohistochemical (IHC) staining of aggrecan, a major PG in the disc, was reduced in the NP and endplate regions in discs of aged PAPPA\(^{-/-}\) mice compared to their Wt littermates (Figure 1B). Taken together, these qualitative and quantitative measurements show decreased PG content in aged mice discs with decreased IGF-1 signaling (PAPPA\(^{-/-}\)) compared to Wt. These findings are consistent with the previous studies that reported the pro-anabolic effects of IGF-1 on matrix production in disc cell culture.\(^{16,34,35}\)

3.2 Aged PAPPA\(^{-/-}\) mice had less fragmented aggregcan in disc

Since disc matrix homeostasis is determined by anabolic and catabolic matrix metabolism, decreased disc PG content in PAPPA\(^{-/-}\) mice could be due to enhanced PG catabolism.\(^{12}\) With aging, disc cells gradually lose their capacity to synthesize new PG to replace what is degraded and lost over time, resulting in a net loss of disc PG.\(^{12}\) A schematic of mouse PG is pictured in Figure 2A, indicating the cleavage sites of MMPs and ADAMTSs between the G1 and G2 globular domains of the aggregcan core protein. G1-VDIPEN360 and G1-NVTEGE392 are G1-bearing N-terminal products generated by MMPs and ADAMTSs, respectively, which can be measured by Western blot. Six-month-old Wt mice were included as a young healthy control, which have little to no disc aggregcan fragmentation (Figure 2B,C). With age, there was a significant increase in the amount of disc aggregcan fragmentation from both MMPs and ADAMTS-mediated cleavage within the interglobular domain of aggregcan (Figure 2B,C). Twenty-three-month-old Wt mice had significantly more ADAMTS-generated and MMP-

| Score (mean ± SD) | Old Wt (23 mo) | Old PAPPA\(^{-/-}\) (23 mo) |
|-------------------|--------|----------------|
| NP cellularity loss | 1.1 ± 0.8 | 2.0 ± 1.0 |
| NP clefts/fissures | 1.1 ± 0.8 | 1.2 ± 0.7 |
| AF structure | 1.3 ± 0.7 | 1.4 ± 0.7 |
| AF clefts/fissures | 1.0 ± 0.6 | 1.2 ± 0.8 |
| AF/NP boundary | 1.3 ± 0.8 | 1.5 ± 1.1 |
| Composite score | 5.8 ± 1.7 | 7.3 ± 1.9 |

Abbreviations: AF, annulus fibrosus; NP, nucleus pulposus; PAPPA, pregnancy-associated plasma protein A; WT, wild-type.
generated aggrecan fragments compared to 6-month-old Wt controls. However, in the aged 23-month-old PAPPA−/− mice, there were significant decreases in the amounts of aggrecan fragmentation from both MMPs and ADAMTS' compared to their Wt littermates (Figure 2B,C). Specifically, the amount of ADAMTS cleaved and MMP cleaved aggrecan in aged PAPPA−/− was about 2-fold less than that seen in the Wt littermates. Therefore, decreasing IGF-1 signaling reduces age-related disc aggrecanolysis. This is consistent with findings that decreasing IGF-1 signaling leads to healthier aging and less age-related disorders.

3.3 | Aged PAPPA−/− mice had lowered expression of disc catabolic markers, MMP-3, and ADAMTS-4

MMP-3 and ADAMTS-4 represent the major metalloproteinases found in disc tissue implicated in aggrecanolytic activity. To determine if these two proteases were regulated by IGF-1 signaling, their protein expression levels in disc tissue were measured in PAPPA−/− mice by Western blot. There was a significant decrease in the level of MMP-3 protein in aged PAPPA−/− mice compared to Wt mice littermates (Figure 3A). ADAMTS-4 protein expression was also decreased in aged PAPPA−/− mice compared to Wt littermates, but this decrease was not significant. Compared to the significant decrease in aggrecan fragmentation seen in aged PAPPA−/− mice (Figure 2A,B), the modest decrease

FIGURE 2 Assesment of catabolic activity in disc tissue of 23-month-old PAPPA−/− mice compared to 23-month-old Wt mice. Western blotting and densitometry measurements were performed as described in Section 2. A, A schematic of the mouse aggrecan core protein covalently linked to the sulphate-rich GAG and noncovalently bound to a hyaluronan chain via the link protein. The cleavage sites between G1 and G2 interglobular domains by ADAMTS (G1-NVTEGE392) and MMP (G1VDIPEN360) proteases are indicated. B, Western blot of 23-month-old PAPPA−/− and 23-month-old Wt disc tissues probed for aggrecan fragments. Six-month-old Wt tissues serve as young controls. Arrows indicate two specific cleavage products corresponding to ADAMTS (~65 kD) and MMP (~55 kD). Three replicates per condition. C, Quantification of aggrecan fragment western blot data for 6-month-old Wt, 23-month-old Wt, and 23-month-old PAPPA−/− tissues. Bars represent mean values of three different mouse tissues; error bars indicate SD. All values were normalized to β-actin control. *, P < .05.

FIGURE 3 Assessment of catabolic protease expression in disc tissue of 23-month-old PAPPA−/− mice compared to 23-month-old Wt mice. Data shown are representative immunoblots and densitometric quantification of MMP-3 (A) and ADAMTS-4 (B) protein expression. Bars represent mean values of three different mouse tissues; error bars indicate SD, n = 3. All values were normalized to β-actin control. *, P < .05.
Senescent disc cells have recently been reported to exhibit a catabolic phenotype, called senescence-associated secretory phenotype, and have imbalanced matrix homeostasis. There is a strong correlation between the level of disc cellular senescence and grade of disc degeneration, and growing evidence suggests senescent disc cells are a key driver of age-related IDD. Therefore, the role of IGF-1 in disc cellular senescence was investigated in aged PAPPA−/− mice. When a healthy cell becomes senescent, it develops characteristic morphological changes, which include enlarged and often irregular nuclei. Lamin B1 is a scaffolding component of the nuclear envelope, and its expression has been shown to be inversely correlated with cellular senescence. Expression is the accumulation of DNA damage, which induces p53 expression. Hence, greater p53 expression in a cell indicates greater likelihood of it progressing toward senescence. Compared to aged WT mice, aged PAPPA−/− mice had less p53 protein expression, but this difference was not statistically significant (Figure 4C). Taken together, these data suggest aged PAPPA−/− mice have lower levels of disc cellular senescence compared to old WT littermates.

### 3.4 Aged PAPPA−/− mice had increased disc lamin B1 and decreased p53 expression, indicating reduced disc cellular senescence

Senescent disc cells have recently been reported to exhibit a catabolic phenotype, called senescence-associated secretory phenotype, and have imbalanced matrix homeostasis. There is a strong correlation between the level of disc cellular senescence and grade of disc degeneration, and growing evidence suggests senescent disc cells are a key driver of age-related IDD. Therefore, the role of IGF-1 in disc cellular senescence was investigated in aged PAPPA−/− mice. When a healthy cell becomes senescent, it develops characteristic morphological changes, which include enlarged and often irregular nuclei. Lamin B1 is a scaffolding component of the nuclear envelope, and its expression has been shown to be inversely correlated with cellular senescence.

Compared to WT littermates, aged PAPPA−/− mice had more nuclear lamin B1 IHC staining, as shown by the black arrows, indicating less senescent disc cells in aged PAPPA−/− mice (Figure 4A, right). Aged WT mice had negligible levels of lamin B1 staining, as indicated by black arrows, suggesting higher number of senescent disc cells (Figure 4A, left). To validate this finding, disc protein level of another senescence biomarker, p53, was assessed by Western blot in aged PAPPA−/− mice and their WT littermates. A major driver of cellular senescence is the accumulation of DNA damage, which induces p53 expression. Hence, greater p53 expression in a cell indicates greater likelihood of it progressing toward senescence. Compared to aged WT mice, aged PAPPA−/− mice had less p53 protein expression, but this difference was not statistically significant (Figure 4C). Taken together, these data suggest aged PAPPA−/− mice have lower levels of disc cellular senescence compared to old WT littermates.

### 4 DISCUSSION

Aging is a key contributor to IDD as disc matrix homeostasis becomes imbalanced with age, resulting in a net loss of PG. PAPPA−/− mice have reduced IGF-1 bioavailability. Notably, their serum IGF-1 levels in serum are not significantly different from WT littermates, but they have significantly higher expression levels of inhibitory IGFBP4, the major substrate of PAPPA protein. As such PAPPA−/− mice have decreased IGF-1 bioavailability. IGF1 protein level, when normalized to beta actin as assessed by Western blot, is similar in disc tissue of PAPPA−/− mice compared to WT mice (Supplemental Fig S1), consistent with the known function of PAPPA in that its depletion is expected to decrease IGF1 bioavailability but not IGF1 protein expression or stability. Consistent with reports about the impact of deletions of components of the IGF system in other animal models, PAPPA−/− mice live on average about 40% longer compared to WT mice. Here, disc matrix characteristics in aged PAPPA−/− mice were shown to be distinct from that of their WT littermates. Specifically, the present data show that discs of aged PAPPA−/− mice exhibit overall reduced aging in the disc as reflected in decreased disc by cellular senescence and aggrecanolysis. These data are consistent with previous findings that PAPPA−/− mice have an overall healthier longevity.
with significantly reduced pathology at mid-life and end-of-life.\textsuperscript{30} Thus, reducing IGF-1 bioavailability in PAPPA\textsuperscript{−/−} mice had a positive effect in regulating disc matrix homeostasis during aging.

PAPPA\textsuperscript{−/−} mice exhibit reduced disc matrix catabolism (Figure 2A, B). In the center of the disc, the gelatinous NP loses water content with age due to proteolytic degradation of aggregan, the major PG in the disc.\textsuperscript{12} With increasing age, there is an increase in expression of disc proteases that break down aggregan molecules for tissue remodeling in response to time-dependent accumulation of injuries and damage. However, this becomes pathological when the remaining cells in the NP can no longer synthesize enough extracellular matrix (including aggregan) to replace what is being degraded.\textsuperscript{12} Compared to Wt littermates, discs of aged PAPPA\textsuperscript{−/−} mice exhibit significantly less aggrecanolysis (Figure 2), significantly decreased expression of the catabolic enzyme MMP-3 (Figure 3), as well as lowered cellular senescence (Figure 4). These findings suggest that age-related changes in the disc occurs more slowly in PAPPA\textsuperscript{−/−} mice, which is consistent with their increased lifespan (40%) compared to that of Wt mice. In other words, PAPPA\textsuperscript{−/−} mice age more slowly than their Wt counterpart and at 23 months of age, the discs of PAPPA\textsuperscript{−/−} mice exhibit less PG catabolism and cellular senescence. It is also plausible that IGF-1 regulates disc aggrecanolysis through its influences on cellular senescence, that is, decreased IGF-1 signaling led to decreased disc aggrecanolysis through suppressing the development of disc cellular senescence. In congruence with this, it has recently been shown that senescent disc cells are catabolic, producing an abundant amount of MMPs that enhance aggrecanolysis on disc tissue.\textsuperscript{37,38} Additionally, studies using human primary fibroblast IMR90 cells and mouse embryonic fibroblasts (MEFs) have reported that prolonged IGF-1 treatment induces premature cellular senescence in a p53-dependent manner.\textsuperscript{39} These findings support the idea that suppressed IGF-1 signaling in PAPPA\textsuperscript{−/−} mice leads to reduced disc cellular senescence which results in an overall decrease in disc aggrecanolysis. On the contrary, Gruber and coworkers reported that supplementing IGF-1 in cell culture rescues AF cells from oxidative stress-induced premature senescence.\textsuperscript{20} These conflicting findings in IGF-1 regulation of disc cellular senescence might be due to the differences between their in vitro condition and our in vivo model as well as the potential metabolic differences between AF and NP cells in responding to stress. Additionally, IGF-1 might also influence disc aggrecanolysis through the AKT pathway which has been implicated in regulating MMP expression,\textsuperscript{40} although confirmatory studies are needed.

The PG content in the disc of 23-month-old PAPPA\textsuperscript{−/−} mice is less than that seen in 23-month-old Wt mice, as demonstrated by safranin-O/fast green histology, DMMB assay for total GAG, and aggregan IHC (Figure 1). This finding is consistent with the pro-anabolic function of IGF-1 as a growth factor, that is, less IGF-1 signaling in PAPPA\textsuperscript{−/−} mice leads to less matrix synthesis during development and less overall disc PG matrix. Previous work demonstrated IGF-1 as an anabolic agent for discs able to promote both PG synthesis and disc cell proliferation.\textsuperscript{11,16,17,19,34,35,41} Concurrently, IGF-1 also stimulated matrix production in chondrocytes. Loeser and coworkers reported significant increases in PG synthesis by chondrocytes derived from knees of osteoarthritis patients that were cultured in alginate beads with exogenous IGF-1 (100-1000 ng/mL).\textsuperscript{42} Increased PG synthesis in bovine monolayer articular chondrocytes and explant models stimulated with IGF-1 were also documented.\textsuperscript{34,35,41,43} Given the pro-anabolic function of IGF-1 on cells, it is possible that the low disc PG in PAPPA\textsuperscript{−/−} mice is due to lack of anabolic stimulation from IGF-1 since birth. Another possibility is PAPPA\textsuperscript{−/−} mice have a decreased ability to synthesize new disc PG matrix as it is lost with age due to increased PG catabolism. The metabolic effects of IGF-1 on disc PG matrix homeostasis.

IGF-1 has been suggested as a therapeutic growth factor to stimulate PG synthesis to counteract the loss of disc PG with age and degeneration. However, the role of IGF-1 in regulating disc matrix homeostasis is more complex than merely up regulating matrix production as reported in vitro studies. Our study comparing Wt and PAPPA\textsuperscript{−/−} mice suggest that IGF-1 signaling is also required for disc PG production in vivo, but prolonged signaling of IGF-1 increases the risk of cellular senescence and aggrecanolysis, as seen in aged Wt mice. Furthermore, in order to synthesize new matrix following stimulation with IGF-1, cells in the degenerated or aged disc must have the nutrients required to generate energy to perform these functions. However, the disc nutrient supply is decreased in most aged and degenerated discs due to end plate calcification.\textsuperscript{34,45} Thus, IGF-1 stimulation of matrix production under this limited nutrient status would likely induce bioenergetic stress in aged or degenerated discs. Adding to the complications of using exogenously administered IGF-1 as a therapeutic approach for IDD patients, Le Maitre et al. found IGF1R expression in the ingrowing blood vessels that characterize part of the etiology in IDD.\textsuperscript{46} Therefore, adding IGF-1 may exacerbate angiogenesis of the ingrowing blood vessels in degenerated discs. Lasty, Zhu et al. found higher levels of IGF-1 in NP cells from lumbar disc herniation patients compared to controls, and a positive relationship between severity of LDH and IGF-1 levels,\textsuperscript{47} which implicate detrimental effects of high IGF-1 level in IDD. Given the observed complexity of IGF-1 in modulating cellular metabolism and disc matrix homeostasis, more studies are needed before this signaling pathway can be considered as a therapeutic target to treat IDD. It should be noted that IGF-1 action on the discs in our global PAPPA knockout mice could be due to its direct effects, that is, IGF-1 entering disc tissue and stimulating disc cells, or indirect effects through impacting other body tissues which then affecting disc tissue via paracrine or endocrine pathways; it is not possible to differentiate between these two mechanisms, adding to the complexity of IGF-1 action on disc biology that would require further investigation to elucidate. Nevertheless, this study suggests that decreasing global IGF-1 bioavailability is overall beneficial for slowing down age-associated IDD, but more temporal and spatial studies aimed at upregulating and down-regulating IGF-1 signaling are needed to further elucidate the mechanisms by which it impacts disc matrix homeostasis and age-associated IDD.

**ACKNOWLEDGMENTS**

The authors Jessa Darwin for her technical contributions, and Patricia Griffin for maintenance and genetic screening of the animal colony,
and isolation of spines for experimental analysis. This project was supported by grants from the National Institute of Health (NIA R01 AG044376 to N. V.), the Department of Orthopaedic Surgery, the Albert B. Ferguson, Jr. MD Fund of the Pittsburgh Foundation, the CURE Program of the Commonwealth of Pennsylvania (A. N. V.), and the American Federation for Aging Research (M12589 to A. N. V.).

CONFLICT OF INTEREST
The authors declare no potential conflict of interest.

AUTHOR CONTRIBUTIONS
Rebecca Kritschil, Joon Lee, Gowendolyn Sowa, Abbe N. Vallejo, and Nam Vo: Research design and/or data interpretation, Drafting and revising manuscript, read and approved the final submitted manuscript. Zhongying Zhang, Changbin Lei, Jongbiao Zhong, Qing Dong, and Cheryl A. Conover: Data acquisition, read and approved the final submitted manuscript.

ORCID
Rebecca Kritschil https://orcid.org/0000-0001-5056-0020
Changbin Lei https://orcid.org/0000-0002-3978-4725
Nam Vo https://orcid.org/0000-0002-1265-8921

REFERENCES
1. Vitale G, Pellegrino G, Vollery M, Hofland LJ. ROLE of IGF-1 system in the modulation of longevity: controversies and new insights from a centenarians’ perspective. Front Endocrinol. 2019;10:27. https://doi.org/10.3389/fendo.2019.00027.
2. Swindell WR, Masternak MM, Bartke A. In vivo analysis of gene expression in long-lived mice lacking the pregnancy-associated plasma protein a (PappA) gene. Exp Gerontol. 2010;45(5):366-374. https://doi.org/10.1016/j.exger.2010.02.009.
3. Mao K, Quipildor GF, Tazearslan C, Huang J, Barzilai N, Suh Y. Impaired IGF1R signaling in premature senescence mice and its role in skeletal aging. Exp Gerontol. 2011;46(10):1710-1718. https://doi.org/10.1016/j.exger.2011.07.015.
4. Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in aging and longevity. Nat Rev Endocrinol. 2013;9(6):366-376. https://doi.org/10.1038/nrendo.2013.67.
5. Senari M, Cordero-Escudero M, Palacios-Vargas R, Lopez-Sevilla S, Lopez-Gonzalez G. The JAK/STAT pathway in aging liver: a complex network of signals. Aging Cell. 2010;9(6):763-773. https://doi.org/10.1111/j.1474-9726.2010.01024.x.
6. Ye X, Dong J, Yamagami K, Suh Y, Wang B, Bartke A, et al. Impaired IGF1R signaling in adult mice lacking the pregnancy-associated plasma protein a. J Biol Chem. 2012;287(22):18730-18739. https://doi.org/10.1074/jbc.M112.352331.
7. Kenyon CJ. The genetics of ageing. Nature. 2012;482(7386):437-444. https://doi.org/10.1038/nature10910.
8. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012;61(6):1315-1322. https://doi.org/10.2337/db11-1300.
9. Patel S, Quipildor GF, Barzilai N, Huffman DM, Milman S. 40 YEARS of IGF1: IGF1: the Jekyll and Hyde of the aging brain. J Mol Endocrinol. 2016;56(1):T171-T185. https://doi.org/10.1530/JME-16-0093.
10. van Heemst D. Insulin, IGF-1 and longevity. Aging Dis. 2010;1(2):147-157.
11. Masuda K, An HS. Prevention of disc degeneration with growth factors. Eur Spine J. 2006;15(Suppl 3):S422-S432. https://doi.org/10.1007/s00586-006-0149-1.
12. Vo NV, Hartman RA, Yurube T, Jacobs LJ, Sowa GA, Kang JD. Expression and regulation of metalloproteinases and their inhibitors in intervertebral disc aging and degeneration. Spine J. 2013;13(3):331-341. https://doi.org/10.1016/j.spinee.2012.02.027.
13. Roughley PJ. Biology of intervertebral disc aging and degeneration. Spine. 2004;29(23):2691-2699. https://doi.org/10.1097/01.brs.0000146105.53784.b1.
14. Pockert AJ, Richardon SM, Le Maitre CL, et al. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum. 2009;60(4):1242-1249. https://doi.org/10.1002/art.29421.
15. Hughes SPF, Freemont AJ, Hukins DWL, McGregor AH, Roberts S. The pathogenesis of degeneration of the intervertebral disc and emerging therapies in the management of back pain. J Bone Joint Surg Br. 2012;94(10):1298-1304. https://doi.org/10.1302/0301-620X.94B10.28986.
16. Osada R, Ohshima H, Ishihara H, et al. Autocrine/paracrine mecha-
ism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res. 1996;14(5):690-699. https://doi.org/10.1002/jor.1100140503.
17. Thompson JP, Odegaa TR, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine. 1991;16(3):253-260.
18. Li J, Yoon ST, Hutton WC. Effect of bone morphogenetic protein-2 (BMP-2) on matrix production, other BMPs, and BMP receptors in rat intervertebral disc cells. J Spinal Disord Tech. 2004;17(5):423-428. https://doi.org/10.1097/01.sdt.0000012208.85112.5d.
19. Pratsinis H, Kletsas D, PDGF, IGF-1 and IGF-I stimulate the prolifera-
tion of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways. Eur Spine J. 2007;16(11):1858-1866. https://doi.org/10.1007/s00586-007-0408-9.
20. Gruber HE, Hoelscher GL, Ingram JA, Bethea S, Hanley EN. IGF-1 rescues human intervertebral annulus cells from in vitro stress-induced premature senescence. Growth Factors. 2006;26(4):220-225. https://doi.org/10.1007/s10740-006-9051-5.
21. Liu Z-Q, Zhao S, Fu W-Q. IGF-1: the Jekyll and Hyde of the aging brain. Biochem Mol Biol Int. 2007;71(2):175-185. https://doi.org/10.1081/BCM-200080214.
22. Kennon JC, Awad ME, Chutkan N, Devine J, Fuzele S. Current insights on use of growth factors as therapy for intervertebral disc degeneration. Biomol Concepts. 2018;9(1):49-52. https://doi.org/10.1515/bmc-2018-0003.
23. Urasavas A, Karadag M, Ilcol YO, et al. Low level of IGF-1 is obesity may be related to obstructive sleep apnea syndrome. Lung. 2007;185(5):309-314. https://doi.org/10.1007/s10540-007-9026-x.
24. Minuto F, Barreca A, Del Monte P, et al. Spontaneous growth hormone and somatotrophin-C/insulin-like growth factor-I secretion in obese subjects during puberty. J Endocrinol Invest. 1988;11(7):489-495. https://doi.org/10.1007/bf03350166.
25. Engström BE, Karlsson FA, Wide L. Gender differences in diurnal growth hormone and epinephrine values in young adults during ambulation. Clin Chem. 1999;45(8 Pt 1):1235-1239.
26. Miller KK, Biller BMK, Lipman JG, Bradwin G, Rifai N, Klibanski A. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab. 2005;90(2):768-774. https://doi.org/10.1210/jc.2004-0894.
27. Conover CA, Bale LK, Overgaard MT, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development. 2004;131(5):1187-1194. https://doi.org/10.1242/dev.00997.
28. Monget P, Oxvig C, PAPP-A and the IGF system. Ann Endocrinol. 2012;77(2):90-96. https://doi.org/10.1016/j.annder.2012.04.015.
29. Bale LK, West SA, Conover CA. Inducible knockdown of pregnancy-associated plasma protein-A gene expression in adult female mice.
extends life span. Aging Cell. 2017;16(4):895-897. https://doi.org/10.1111/ace.12624.

30. Conover CA, Bale LK, Mader JR, Mason MA, Keenan KP, Marler RJ. Longevity and age-related pathology of mice deficient in pregnancy-associated plasma protein-a. J Gerontol A Biol Sci Med Sci. 2010;65(6):590-599. https://doi.org/10.1093/gerona/glq032.

31. Ngo K, Pohl P, Wang D, et al. ADAMT5 deficiency protects mice from chronic tobacco smoking-induced intervertebral disc degeneration. Spine. 2017;42(20):1521-1528. https://doi.org/10.1097/BRS.0000000000002258.

32. Fardale R, Buttle D, Barrett A. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta Gen Subj. 1986;883(2):173-177. https://doi.org/10.1016/0304-4165(86)90306-5.

33. Studer RK, Gilbertson LG, Georgescu H, Sowa G, Vo N, Kang JD. p38 MAPK inhibition modulates rabbit nucleus pulposus cell response to IL-1. J Orthop Res. 2008;26(7):991-998. https://doi.org/10.1002/jor.20604.

34. McQuillan DJ, Handley CJ, Campbell MA, Bolis S, Milway VE, Herington AC. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J. 1986;240(2):423-430. https://doi.org/10.1042/bj2400423.

35. Luyten FP, Hascall VC, Nissley SP, Morales TI, Reddi AH. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys. 1988;267(2):416-425. https://doi.org/10.1016/0003-9861(88)90047-1.

36. Feng C, Liu H, Yang M, Zhang Y, Huang B, Zhou Y. Disc cell senescence in intervertebral disc degeneration: causes and molecular pathways. Cell Cycle. 2016;15(13):1674-1684. https://doi.org/10.1080/15384101.2016.1152433.

37. Patil P, Dong Q, Wang D, et al. Systemic clearance of p16INK4a-positive senescent cells mitigates age-associated intervertebral disc degeneration. Aging Cell. 2019;18(3):e12927. https://doi.org/10.1111/ace.12927.

38. Ngo K, Patil P, McGowan SJ, et al. Senescent intervertebral disc cells exhibit perturbed matrix homeostasis phenotype. Mech Ageing Dev. 2017;166:16-23. https://doi.org/10.1016/j.mad.2017.08.007.

39. Tran D, Bergholz J, Zhang H, et al. Insulin-like growth factor-1 regulates the SIRT1-p53 pathway in cellular senescence. Aging Cell. 2014;13(4):669-678. https://doi.org/10.1111/ace.12219.

40. Fu X, Halim A, Tian B, Luo Q, Song G. MT1-MMP downregulation via the PI3K/Akt signaling pathway is required for the mechanical stretching-inhibited invasion of bone-marrow-derived mesenchymal stem cells. J Cell Physiol. 2019;234(8):14133-14144. https://doi.org/10.1002/jcp.28105.

41. Guenther HL, Guenther HE, Froesch ER, Fleisch H. Effect of insulin-like growth factor on collagen and glycosaminoglycan synthesis by rabbit articular chondrocytes in culture. Experientia. 1982;38(8):979-981. https://doi.org/10.1007/bf01953688.

42. Loesser RF, Todd MD, Seely BL. Prolonged treatment of human osteoarthritic chondrocytes with insulin-like growth factor-I stimulates proteoglycan synthesis but not proteoglycan matrix accumulation in alginate cultures. J Rheumatol. 2003;30(7):1565-1570.

43. Osborn KD, Trippel SB, Mankin HJ. Growth factor stimulation of adult articular cartilage. J Orthop Res. 1989;7(1):35-42. https://doi.org/10.1002/jor.1100070106.

44. Urban JGP, Smith S, Fairbank JCT. Nutrition of the intervertebral disc. Spine. 2004;29(23):2700-2709. https://doi.org/10.1097/01.brs.0000146499.97948.52.

45. Wu Y, Cisewski S, Sachs BL, Yao H. Effect of cartilage endplate on cell based disc regeneration: a finite element analysis. Mol Cell Biomech. 2013;10(2):159-182.

46. Le Maitre CL, Richardson SMA, Baird P, Freemont AJ, Hoyland JA. Expression of receptors for putative anabolic growth factors in human intervertebral disc: implications for repair and regeneration of the disc. J Pathol. 2005;207(4):445-452. https://doi.org/10.1002/path.1862.

47. Zhu Z, Huang P, Chong Y, et al. Nucleus pulposus cells derived IGF-1 and MCP-1 enhance osteoclastogenesis and vertebrae disruption in lumbar disc herniation. Int J Clin Exp Pathol. 2014;7(12):8520-8531.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.